Adverse events associated with treatment · Adults with oral cavity cancer (tongue or floor of mouth) and clinically negative neck nodes
1 finding from 1 review
Adverse events associated with treatment · Adults with oral cavity or oropharyngeal cancer
1 finding from 1 review
Adverse events: significant difference in complication rates, lower for supraomohyoid (SOND 13.0% vs MRND 21.9%, P=0.040). UW-QOL at 1 year: supraomohyoid superior in pain relief (78.8% vs 75.2%, P=0.013) and shoulder…
1 study · 332 participants
Very low
Adverse events associated with treatment · Adults with oral cavity or oropharyngeal cancer
1 finding from 1 review
Adverse events: severe acute effects in both groups (subcutaneous fibrosis, telangiectasia, moderate-to-severe oedema, xerostomia, trismus, dysphagia); subcutaneous fibrosis more prevalent with surgery + radiotherapy…
1 study · 35 participants
Very low
Adverse events associated with treatment · Adults with oral cavity or oropharyngeal cancer with nodal disease (stage N2 or N3)
1 finding from 1 review
Proportion of people with adverse events · people with primary sclerosing cholangitis
It is very uncertain whether ursodeoxycholic acid changes proportion of people with adverse events compared with placebo (very low certainty).
1 finding from 1 review
Maternal Grade 3/4 Severe Adverse Events · HIV‐infected mothers and their breastfeeding infants
It is very uncertain whether an extended ZDV/3TC/LPV/r regimen administered to mothers changes maternal Grade 3/4 Severe Adverse Events compared with short course ZDV (intrapartum ZDV/3TC/sdNVP) (very low certainty).
1 finding from 1 review
Adverse events: Dysphagia‐related complications Occurrence of dysphagia‐related complications: pneumonia, dehydration, mucositis and oral yeast infection · adults with advanced head and neck cancer
1 finding from 1 review
Gastrointestinal bleeding · minimal change disease in adults with nephrotic syndrome
It is very uncertain whether intravenous ± oral steroids changes adverse events: gastrointestinal bleeding compared with oral steroids alone (very low certainty).
1 finding from 1 review
Doubling serum creatinine · minimal change disease in adults with nephrotic syndrome
It is very uncertain whether steroids changes adverse events: doubling serum creatinine compared with no specific treatment (very low certainty).
1 finding from 1 review
Treatment cessation due to adverse events · CRRT
Unfractionated heparin showed no clear difference in treatment cessation due to adverse events compared with low molecular weight heparin (low certainty).
1 finding from 1 review
Treatment cessation due to adverse events · CRRT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment cessation due to adverse events · CRRT
Citrate showed no clear difference in treatment cessation due to adverse events compared with unfractionated heparin (low certainty).
1 finding from 1 review
Adverse events: persistent nephrotoxicity · idiopathic steroid‐resistant nephrotic syndrome in children
Tacrolimus showed no clear difference in adverse events: persistent nephrotoxicity compared with cyclosporin (low certainty).
1 finding from 1 review
Adverse events: worsening of hypertension · idiopathic steroid‐resistant nephrotic syndrome in children
1 finding from 1 review
Adverse events: worsening of hypertension · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether cyclosporin changes adverse events: worsening of hypertension compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Serious adverse events (number of events) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number of events) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: including serious adverse events, vaso‐occlusive crisis, gastrointestinal disorder, headache or migraine, upper respiratory tract infection, rash · people with sickle cell disease
1 finding from 1 review
Dropouts due to adverse events · adults experiencing acute traumatic stress symptoms
1 finding from 1 review
Dropouts due to adverse events · adults experiencing acute traumatic stress symptoms
Hydrocortisone showed no clear difference in dropouts due to adverse events at 3 months compared with placebo (low certainty).
1 finding from 1 review